Exagen Inc.

DB:E08A Stock Report

Market Cap: €87.3m

Exagen Valuation

Is E08A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of E08A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: E08A (€4.86) is trading below our estimate of fair value (€24.57)

Significantly Below Fair Value: E08A is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for E08A?

Key metric: As E08A is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for E08A. This is calculated by dividing E08A's market cap by their current revenue.
What is E08A's PS Ratio?
PS Ratio1.6x
SalesUS$55.75m
Market CapUS$90.83m

Price to Sales Ratio vs Peers

How does E08A's PS Ratio compare to its peers?

The above table shows the PS ratio for E08A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.8x
HPHA Heidelberg Pharma
12x16.6%€101.6m
2INV 2invest
8.7xn/a€67.3m
MDG1 Medigene
2x13.3%€15.2m
CNW co.don
0.7xn/a€6.5m
E08A Exagen
1.6x13.7%€90.8m

Price-To-Sales vs Peers: E08A is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (7.6x).

Price to Sales Ratio vs Industry

How does E08A's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.5x3.6%US$1.40b
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
E08A 1.6xIndustry Avg. 8.2xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: E08A is good value based on its Price-To-Sales Ratio (1.6x) compared to the European Biotechs industry average (8.2x).

Price to Sales Ratio vs Fair Ratio

What is E08A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

E08A PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.6x
Fair PS Ratio1.8x

Price-To-Sales vs Fair Ratio: E08A is good value based on its Price-To-Sales Ratio (1.6x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst E08A forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€4.86
€5.89
+21.1%
20.8%€7.53€4.71n/a4
Dec ’25€3.56
€5.89
+65.3%
20.8%€7.53€4.71n/a4
Nov ’25€2.20
€5.70
+159.3%
20.8%€7.30€4.56n/a4
Oct ’25€2.72
€5.70
+109.7%
20.8%€7.30€4.56n/a4
Sep ’25€2.66
€5.70
+114.4%
20.8%€7.30€4.56n/a4
Aug ’25€1.81
€5.54
+206.3%
16.7%€6.47€4.62n/a4
Jul ’25€1.66
€5.54
+234.0%
16.7%€6.47€4.62n/a4
Jun ’25€1.74
€5.54
+218.7%
16.7%€6.47€4.62n/a4
May ’25€1.29
€5.06
+292.4%
15.7%€6.44€4.60n/a4
Apr ’25€1.42
€5.06
+256.5%
15.7%€6.44€4.60n/a4
Mar ’25€2.04
€5.29
+159.1%
14.4%€6.44€4.60n/a4
Feb ’25€1.96
€5.29
+169.7%
14.4%€6.44€4.60n/a4
Jan ’25€1.81
€5.29
+192.0%
14.4%€6.44€4.60n/a4
Dec ’24€1.84
€5.29
+187.3%
14.4%€6.44€4.60€3.564
Nov ’24€1.59
€5.43
+241.4%
14.4%€6.61€4.72€2.204
Oct ’24€2.30
€5.92
+157.3%
13.3%€6.63€4.73€2.724
Sep ’24€2.30
€5.70
+147.9%
13.3%€6.39€4.56€2.664
Aug ’24€2.16
€5.76
+166.5%
13.3%€6.45€4.61€1.814
Jul ’24€2.68
€5.76
+114.8%
13.3%€6.45€4.61€1.664
Jun ’24€2.90
€5.76
+98.5%
13.3%€6.45€4.61€1.744
May ’24€2.30
€5.72
+148.6%
13.3%€6.40€4.57€1.294
Apr ’24€2.26
€5.75
+154.6%
13.3%€6.44€4.60€1.424
Mar ’24€2.38
€5.99
+151.5%
7.7%€6.45€5.53€2.044
Feb ’24€2.60
€5.99
+130.2%
7.7%€6.45€5.53€1.964
Jan ’24€2.24
€7.06
+215.3%
11.5%€8.48€6.59€1.814
Dec ’23€2.54
€7.21
+183.9%
11.5%€8.65€6.73€1.844

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 01:24
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Exagen Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Kyle MiksonCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.